Format

Send to

Choose Destination
J Neurol. 2017 Mar;264(3):541-553. doi: 10.1007/s00415-016-8379-6. Epub 2017 Jan 10.

Reduced serum myostatin concentrations associated with genetic muscle disease progression.

Author information

1
Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA. peter.m.burch2@gmail.com.
2
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
3
Worldwide Research and Development, Pfizer Inc., 1 Burtt Rd, Andover, MA, USA.
4
Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA.
5
Worldwide Research and Development, Pfizer Inc., 610 Main St., Cambridge, MA, USA.
6
Solid Biosciences, 161 First St., Cambridge, MA, 02142, USA.

Abstract

Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC-MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.

KEYWORDS:

Biomarker; Mass spectrometry; Myostatin; Neuromuscular disease

PMID:
28074267
DOI:
10.1007/s00415-016-8379-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center